Steroidogenesis inhibitor ODM-209 for metastatic castration-resistant prostate cancer and advanced breast cancer: Results from the first-in-human STESIDES study

Authors:

Abstract
No abstract available
Funding Information
  • MSD Sharp and Dohme
  • Merck
  • Orion Corporation
  • Merck Sharp and Dohme United Kingdom

This publication has 34 references indexed in Scilit: